MRI perfusion in determining pseudoprogression in patients with glioblastoma

Clin Imaging. Jan-Feb 2013;37(1):41-9. doi: 10.1016/j.clinimag.2012.02.016. Epub 2012 Jun 8.

Abstract

We examine the role of dynamic susceptibility contrast (DSC) magnetic resonance imaging (MRI) perfusion in differentiating pseudoprogression from progression in 20 consecutive patients with treated glioblastoma. MRI perfusion was performed, and relative cerebral blood volume (rCBV), relative peak height (rPH), and percent signal recovery (PSR) were measured. Pseudoprogression demonstrated lower median rCBV (P=.009) and rPH (P<.001), and higher PSR (P=.039) than progression. DSC MRI perfusion successfully identified pseudoprogression in patients who did not require a change in treatment despite radiographic worsening following chemoradiotherapy.

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Aged, 80 and over
  • Brain Neoplasms / epidemiology
  • Brain Neoplasms / pathology*
  • Brain Neoplasms / therapy*
  • Child
  • Disease Progression
  • Disease-Free Survival
  • Female
  • Glioblastoma / epidemiology
  • Glioblastoma / pathology*
  • Glioblastoma / therapy*
  • Humans
  • Magnetic Resonance Angiography / methods*
  • Male
  • Middle Aged
  • Neoplasm Recurrence, Local / epidemiology
  • Neoplasm Recurrence, Local / pathology*
  • Neoplasm Recurrence, Local / prevention & control*
  • New York / epidemiology
  • Prevalence
  • Risk Factors
  • Treatment Outcome
  • Young Adult